scholarly journals Central obesity and nonalcoholic fatty liver disease in people living with HIV: a case for targeted screening?

HIV Medicine ◽  
2018 ◽  
Vol 20 (1) ◽  
pp. e1-e2 ◽  
Author(s):  
C Dewar ◽  
QM Anstee ◽  
DA Price ◽  
BAI Payne
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Central Obesity ◽  
People Living With Hiv ◽  
Nonalcoholic Fatty Liver ◽  
Targeted Screening ◽  
Living With Hiv

Nonalcoholic fatty liver disease and steatohepatitis in people living with HIV

2019 ◽  
Vol 13 (7) ◽  
pp. 643-650 ◽  
Author(s):  
Nicola Squillace ◽  
Alessandro Soria ◽  
Giorgio Bozzi ◽  
Andrea Gori ◽  
Alessandra Bandera
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
People Living With Hiv ◽  
Nonalcoholic Fatty Liver ◽  
Living With Hiv

scholarly journals Liver steatosis and nonalcoholic fatty liver disease with fibrosis are predictors of frailty in people living with HIV

AIDS ◽  
2020 ◽  
Vol 34 (13) ◽  
pp. 1915-1921
Author(s):  
Jovana Milic ◽  
Valentina Menozzi ◽  
Filippo Schepis ◽  
Andrea Malagoli ◽  
Giulia Besutti ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Liver Steatosis ◽  
People Living With Hiv ◽  
Nonalcoholic Fatty Liver ◽  
Living With Hiv

Emerging prevalence of fatty liver disease in HIV

2021 ◽  
Vol 16 (1) ◽  
pp. 59-73
Author(s):  
Amreen Dinani ◽  
Ali Khan ◽  
Douglas Dieterich
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Unmet Need ◽  
Hiv Care ◽  
People Living With Hiv ◽  
Nonalcoholic Fatty Liver ◽  
Infected People ◽  
Direct Acting ◽  
Living With Hiv

Fatty liver disease is a growing concern in people living with HIV, the main drivers are alcoholic liver disease and nonalcoholic fatty liver disease. It has shown to negatively impact HIV care continuum and result in notable non-HIV related morbidity and mortality. With the advancement in antiretroviral therapy and effective direct acting antivirals, fatty liver disease is surfacing as the next big challenge in this population like that observed in the general population. This review article summarizes the gravity of these two common diseases in HIV-infected people and aims to sheds light on an unmet need to develop effective methods to identify, screen and manage fatty liver disease in this unique population.

scholarly journals Relationship between Dietary Fatty Acid Intake with Nonalcoholic Fatty Liver Disease and Liver Fibrosis in People with HIV

Nutrients ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 3462
Author(s):  
Cristiane Fonseca de Almeida ◽  
Paula Simplicio da Silva ◽  
Claudia Santos de Aguiar Cardoso ◽  
Nathalia Gorni Moreira ◽  
Julliana Cormack Antunes ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Protective Factor ◽  
Hiv Care ◽  
People Living With Hiv ◽  
Nonalcoholic Fatty Liver ◽  
Total Fat

We aimed to evaluate the relationship between food intake of lipids with nonalcoholic fatty liver disease (NAFLD) and/or liver fibrosis in people living with HIV/AIDS (PLWHA). In this cross-sectional study, transient elastography was used to detect the presence of NAFLD and/or liver fibrosis. The dietary intake of fats and fatty acids (FA) were assessed by two 24 h dietary recalls (24-HDR) (n = 451). Multivariate logistic regression models were performed. Participants with higher intake of total fat were associated with higher odds for NAFLD compared to those with lower consumption [adjusted odds ratio (aOR) = 1.91 (95% confidence interval (95% CI) 1.06–3.44)]. Furthermore, participants with intermediate intake of n6-PUFA (n6-poly-unsaturated FA) and lauric FA had lower odds for NAFLD, respectively aOR = 0.54 (95% CI 0.3–0.98) and aOR = 0.42 (95% CI 0.22–0.78). Additionally, a higher intake of myristoleic FA (fourth quartile) was a significant protective factor for NAFLD [aOR = 0.56 (95% CI 0.32–0.99)]. Participants with higher intake of lauric FA [0.38 (95% CI 0.18–0.80)], myristic FA [0.38 (0.17–0.89)], palmitoleic FA [0.40 (0.19–0.82)] and oleic FA [0.35 (0.16–0.79)] had positively less odds of having liver fibrosis. On the other hand, higher intake of n-6 PUFA was significantly associated with fibrosis [aOR = 2.45 (95% CI 1.12–5.32)]. Dietary assessment of total fat and FA should be incorporated into HIV care as a tool for preventing NAFLD and fibrosis in PLWHA.

scholarly journals Serum omentin-1, vaspin, and apelin levels and central obesity in patients with nonalcoholic fatty liver disease

2017 ◽  
Vol 22 (1) ◽  
pp. 70 ◽  
Author(s):  
Mansour Karajibani ◽  
Farzaneh Montazerifar ◽  
AliReza Bakhshipour ◽  
Zahra Torki ◽  
AliReza Dashipour
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Central Obesity ◽  
Nonalcoholic Fatty Liver
Sign in / Sign up

Export Citation Format

Share Document